Variants in STAT5B associate with serum TC and LDL-C levels.

CONTEXT Known genetic variants influencing serum lipid levels do not adequately account for the observed population variability of these phenotypes. The GH/signal transducers and activators of transcription (STAT) signaling pathway is an evolutionary conserved system that exerts strong effects on metabolism, including that of lipids. RESEARCH DESIGN AND METHODS We analyzed the association of 11 single-nucleotide polymorphisms (SNP) spanning the STAT5B/STAT5A/STAT3 locus with serum lipid levels in six European populations (n = 5162 nondiabetic individuals). RESULTS After adjustment for age, sex, alcohol use, smoking, and body mass index, we identified STAT5B variants (rs8082391 and rs8064638) in novel association with total cholesterol (TC; P = 0.001 and P = 0.002) and low-density lipoprotein cholesterol (P = 0.002 and P = 0.004) levels. The minor alleles of these single-nucleotide polymorphisms were significantly enriched in hyperlipidemic individuals across the six discovery populations (P = 0.004 and P = 0.006). In transgenic mice deficient for hepatic STAT5A and STAT5B, reduced serum TC levels coincided with reduced hepatic cholesterol biosynthesis as demonstrated using gene expression profiling and pathway enrichment analysis. CONCLUSIONS Genetic variants in STAT5B are associated with TC and low-density lipoprotein cholesterol levels among six populations. Mechanistically, STAT5B transcriptionally regulates hepatic cholesterol homeostasis.

[1]  T. Rice,et al.  Application of three-level linear mixed-effects model incorporating gene-age interactions for association analysis of longitudinal family data , 2009, BMC proceedings.

[2]  J. Witteman,et al.  Heritabilities, apolipoprotein E, and effects of inbreeding on plasma lipids in a genetically isolated population: The Erasmus Rucphen Family Study , 2007, European Journal of Epidemiology.

[3]  Anita L. DeStefano,et al.  Evidence for a Gene Influencing Blood Pressure on Chromosome 17: Genome Scan Linkage Results for Longitudinal Blood Pressure Phenotypes in Subjects From the Framingham Heart Study , 2000, Hypertension.

[4]  L. Hennighausen,et al.  Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. , 2008, Genes & development.

[5]  D. Nyholt A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. , 2004, American journal of human genetics.

[6]  A. Hoeflich,et al.  Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. , 2004, Genes & development.

[7]  R. Elston,et al.  The collaborative Lipid Research Clinics family study: Biological and cultural determinants of familial resemblance for plasma lipids and lipoproteins , 1985, Genetic epidemiology.

[8]  E. Casanova,et al.  Disruption of the growth hormone—Signal transducer and activator of transcription 5—Insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis , 2010, Hepatology.

[9]  L. Hennighausen,et al.  Direct glucocorticoid receptor-Stat5 interaction in hepatocytes controls body size and maturation-related gene expression. , 2007, Genes & development.

[10]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[11]  Joseph L Goldstein,et al.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.

[12]  T. Clemens,et al.  Liver-specific Deletion of the Growth Hormone Receptor Reveals Essential Role of Growth Hormone Signaling in Hepatic Lipid Metabolism*♦ , 2009, The Journal of Biological Chemistry.

[13]  I. Dusanter-Fourt,et al.  STAT5 and Oct-1 Form a Stable Complex That Modulates Cyclin D1 Expression , 2003, Molecular and Cellular Biology.

[14]  L. Hennighausen,et al.  Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration , 2007, Hepatology.

[15]  B. Bengtsson,et al.  Growth hormone and the metabolic syndrome. , 1999, Journal of endocrinological investigation.

[16]  R. Davis,et al.  Cholesterol and hepatic lipoprotein assembly and secretion. , 2000, Biochimica et biophysica acta.

[17]  D. Waxman,et al.  Growth hormone regulation of sex-dependent liver gene expression. , 2006, Molecular endocrinology.

[18]  T. Thum,et al.  LOX-1 Receptor Blockade Abrogates oxLDL-induced Oxidative DNA Damage and Prevents Activation of the Transcriptional Repressor Oct-1 in Human Coronary Arterial Endothelium* , 2008, Journal of Biological Chemistry.

[19]  R. Costa,et al.  In vivo regulation of murine CYP7A1 by HNF‐6: A novel mechanism for diminished CYP7A1 expression in biliary obstruction , 2004, Hepatology.

[20]  D. Peake,et al.  Liver-specific Deficiency of Serine Palmitoyltransferase Subunit 2 Decreases Plasma Sphingomyelin and Increases Apolipoprotein E Levels* , 2009, The Journal of Biological Chemistry.

[21]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  A. Dobson,et al.  Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations , 2000, The Lancet.

[23]  Sander M Houten,et al.  Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. , 2004, The Journal of clinical investigation.

[24]  J. Li,et al.  Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix , 2005, Heredity.